183 related articles for article (PubMed ID: 27016225)
1. Initiation of a formalized precision medicine program in gynecologic oncology.
Gunderson CC; Rowland MR; Wright DL; Andrade KL; Mannel RS; McMeekin DS; Moore KN
Gynecol Oncol; 2016 Apr; 141(1):24-8. PubMed ID: 27016225
[TBL] [Abstract][Full Text] [Related]
2. The NCI-MATCH trial and precision medicine in gynecologic cancers.
Barroilhet L; Matulonis U
Gynecol Oncol; 2018 Mar; 148(3):585-590. PubMed ID: 29366510
[TBL] [Abstract][Full Text] [Related]
3. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Rodriguez-Freixinos V; Lheureux S; Mandilaras V; Clarke B; Dhani NC; Mackay H; Butler MO; Wang L; Siu LL; Kamel-Reid S; Stockley T; Bedard PL; Oza AM
Gynecol Oncol; 2019 May; 153(2):304-311. PubMed ID: 30792002
[TBL] [Abstract][Full Text] [Related]
4. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
Penson RT; Sales E; Sullivan L; Borger DR; Krasner CN; Goodman AK; del Carmen MG; Growdon WB; Schorge JO; Boruta DM; Castro CM; Dizon DS; Birrer MJ
Gynecol Oncol; 2016 Apr; 141(1):108-12. PubMed ID: 27016236
[TBL] [Abstract][Full Text] [Related]
5. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
Taghizadeh H; Mader RM; Müllauer L; Aust S; Polterauer S; Kölbl H; Seebacher V; Grimm C; Reinthaller A; Prager GW
Oncologist; 2020 Jul; 25(7):e1060-e1069. PubMed ID: 32369643
[TBL] [Abstract][Full Text] [Related]
6. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
Somasegar S; Hoppenot C; Kuchta K; Sereika A; Khandekar J; Rodriguez G; Moore E; Hurteau J; Vogel TJ
Gynecol Oncol; 2021 Nov; 163(2):220-228. PubMed ID: 34511240
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of gynecologic cancers and implications for clinical practice.
Prendergast EN; Elvin JA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):18-25. PubMed ID: 27984344
[TBL] [Abstract][Full Text] [Related]
9. Is the NCI MATCH trial a match for gynecologic oncology?
Moore KN; Mannel RS
Gynecol Oncol; 2016 Jan; 140(1):161-6. PubMed ID: 26586415
[TBL] [Abstract][Full Text] [Related]
10. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.
Sa JK; Hwang JR; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim J; Kim MS; Paik ES; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee Y; Her NG; Shin YJ; Cho HJ; Kim JY; Seo YJ; Koo H; Oh JW; Lee T; Kim HS; Song SY; Bae JS; Park WY; Han HD; Ahn HJ; Sood AK; Rabadan R; Lee JK; Nam DH; Lee JW
Genome Biol; 2019 Nov; 20(1):253. PubMed ID: 31771620
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.
Nie Q; Omerza G; Chandok H; Prego M; Hsiao MC; Meyers B; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rowe S; Rueter J; Reddi HV
Cancer Genet; 2020 Apr; 242():25-34. PubMed ID: 31992506
[TBL] [Abstract][Full Text] [Related]
13. Impact of molecular testing in clinical practice in gynecologic cancers.
Huang M; Hunter T; Slomovitz B; Schlumbrecht M
Cancer Med; 2019 May; 8(5):2013-2019. PubMed ID: 30848097
[TBL] [Abstract][Full Text] [Related]
14. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
[TBL] [Abstract][Full Text] [Related]
15. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
16. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.
Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Burges A; Trillsch F; Mahner S; Harbeck N; Wuerstlein R
Arch Gynecol Obstet; 2021 May; 303(5):1331-1345. PubMed ID: 33277683
[TBL] [Abstract][Full Text] [Related]
17. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
18. PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.
Thouvenin J; Van Marcke C; Decoster L; Raicevic G; Punie K; Vandenbulcke M; Salgado R; Van Valckenborgh E; Maes B; Joris S; Steichel DV; Vranken K; Jacobs S; Dedeurwaerdere F; Martens G; Devos H; Duhoux FP; Rasschaert M; Pauwels P; Geboes K; Collignon J; Tejpar S; Canon JL; Peeters M; Rutten A; Van de Mooter T; Vermeij J; Schrijvers D; Demey W; Lybaert W; Van Huysse J; Mebis J; Awada A; Claes KBM; Hebrant A; Van der Meulen J; Delafontaine B; Bempt IV; Maetens J; de Hemptinne M; Rottey S; Aftimos P; De Grève J
ESMO Open; 2022 Aug; 7(4):100524. PubMed ID: 35970014
[TBL] [Abstract][Full Text] [Related]
19. Genomic testing and precision medicine--What does this mean for gynecologic oncology?
Liu J; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2016 Jan; 140(1):3-5. PubMed ID: 26657840
[No Abstract] [Full Text] [Related]
20. Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.
Kraus FBT; Sultova E; Heinrich K; Jung A; Westphalen CB; Tauber CV; Kumbrink J; Rudelius M; Klauschen F; Greif PA; König A; Chelariu-Raicu A; Czogalla B; Burges A; Mahner S; Wuerstlein R; Trillsch F
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
